In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Insulet Corp (PODD), with a price target of $100. The company’s shares closed yesterday at $86.08.
According to TipRanks.com, Kalia is a 5-star analyst with an average return of 10.7% and a 58.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.
Insulet Corp has an analyst consensus of Moderate Buy, with a price target consensus of $104.50.
See today’s analyst top recommended stocks >>
The company has a one-year high of $108.91 and a one-year low of $70.80. Currently, Insulet Corp has an average volume of 658.2K.
Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.
